Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

被引：12
|
作者：
Trudel, Suzanne [1 ]
McCurdy, Arleigh [2 ]
Fu, Molei [3 ]
Sutherland, Heather J. [4 ]
Louzada, Martha L. [5 ]
Chu, Michael P. [6 ]
White, Darrell J. [7 ,8 ]
Mian, Hira S. [9 ]
Kotb, Rami [10 ]
Othman, Ibraheem [11 ]
Kardjadj, Moustafa [12 ]
Gul, Engin [13 ]
Reece, Donna E. [3 ]
机构：
[1] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[2] Ottawa Hosp, Dept Med, Div Hematol, Ottawa, ON, Canada
[3] Canadian Myeloma Res Grp CMRG, Vaughan, ON, Canada
[4] Vancouver Gen Hosp, Div Hematol, Vancouver, BC, Canada
[5] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada
[6] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
[7] Dalhousie Univ, Halifax, NS, Canada
[8] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[9] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[10] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada
[11] Saskatchewan Canc Agcy, Allan Blair Canc Ctr, Regina, SK, Canada
[12] Canadian Myeloma Res Grp, Toronto, ON, Canada
[13] Canadian Myeloma Res Grp CMRG, Concord, ON, Canada
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7306 / 7307
页数：2
相关论文
共 50 条
  • [11] Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
    Neupane, Karun
    Wahab, Ahsan
    Masood, Adeel
    Faraz, Tehniat
    Bahram, Saman
    Ehsan, Hamid
    Hannan, Abdul
    Anwer, Faiz
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 529 - 550
  • [12] BELANTAMAB MAFODOTIN IN A PATIENT WITH REFRACTORY MULTIPLE MYELOMA
    Luz Gema, Roman
    Borja, Puertas
    Alberto, Hernandez
    Sandra, Gomez
    Felipe, Pena
    Danylo, Palomino
    Bea, Rey
    Marta, Fonseca
    Raul, Azibeiro
    Elena, Alejo
    David, Alonso
    Jose Maria, Navarro
    Veronica, Gonzalez
    Noemi, Puig
    Maria Victoria, Mateos
    HAEMATOLOGICA, 2021, 106 (10) : 334 - 334
  • [13] Belantamab mafodotin for relapsed or refractory multiple myeloma
    David Gil-Sierra, Manuel
    del Pilar Briceno-Casado, Maria
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (06) : 1375 - 1380
  • [14] Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Roussou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Spiliopoulou, Vassiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S203 - S204
  • [15] Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
    Dimopoulos, Meletios
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Vorobyev, Vladimir
    Quach, Hang
    Spicka, Ivan
    Radocha, Jakub
    Robak, Pawel
    Kim, Kihyun
    Cavo, Michele
    Suzuki, Kazuhito
    Wilkes, Jodie
    Morris, Kristin
    Pompilus, Farrah
    Purser, Molly
    Philips-Jones, Amy
    Zhou, Xiaoou
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Manteca, Maria-Victoria Mateos
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S9 - S9
  • [16] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    BLOOD, 2016, 128 (22)
  • [17] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Stowell, Delia
    Gupta, Ira
    Wu, Frank S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
  • [18] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
    Sheikh, Semira
    Lebel, Eyal
    Trudel, Suzanne
    FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
  • [19] Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Roussou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Spiliopoulou, Vassiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios-Athanasios
    Gavriatopoulou, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [20] DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
    Nooka, Ajay K.
    Stockerl-Goldstein, Keith
    Quach, Hang
    Forbes, Adam
    Mateos, Maria-Victoria
    Khot, Amit
    Tan, Alan
    Abonour, Rafat
    Chopra, Bikramjit
    Rogers, Rachel
    Ferron-Brady, Geraldine
    Davidge, Jacqueline
    Frey, Steve
    Yeakey, Anne
    Talekar, Mala
    Luptakova, Katarina
    Gupta, Ira
    Popat, Rakesh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345